James Mossell, DO
Rheumatology · Tifton, GANPI 1720195837
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,144,963 of the $1,611,604 with a category attached, or 71.0%. 39 manufacturers reported payments, led by Amgen at 35.2% of the total. Among rheumatology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,843 payments — averaging $566.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$567K
- AbbVie$303K
- Sanofi$178K
- UCB, Inc.$147K
- GSK$96K
- Boehringer Ingelheim$70K
- plus $251K from 33 others
What the payments were for
- Consulting fees$98,7036%
- Speaking & faculty fees$1,144,96371%
- Travel & lodging$315,30920%
- Food & beverage$51,8553%
- Education$7740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,611,604 in reported general payments places this provider in the 95th percentile of 177 rheumatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 171 | $1,763,552 |
| ActharCorticotropin | 18 | $1,418,869 |
| Enbrel MiniEtanercept | 123 | $913,841 |
| Orencia ClickjectAbatacept | 123 | $734,051 |
| BenlystaBelimumab | 106 | $560,624 |
| KevzaraSarilumab | 122 | $529,341 |
| KrystexxaPegloticase | 16 | $456,351 |
| Skyrizi PenRisankizumab-Rzaa | 21 | $431,721 |
| RinvoqUpadacitinib | 55 | $348,970 |
| OrenciaAbatacept | 53 | $297,266 |
| Xeljanz XrTofacitinib Citrate | 29 | $171,626 |
| OtezlaApremilast | 31 | $144,072 |
| Enbrel SureclickEtanercept | 19 | $138,700 |
| Cimzia (2 Pack)Certolizumab Pegol | 19 | $120,404 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $87,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $59,291 | $1,418,86918 claims |
| AmgenKrystexxa, Otezla | $566,775 | $600,42447 claims |
| GSKBenlysta | $95,743 | $560,624106 claims |
| SanofiKevzara | $178,071 | $529,341122 claims |
| AbbVieRinvoq, Savella, Synthroid | $303,276 | $366,879109 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $600 | $297,26653 claims |
| UCB, Inc.Cimzia (2 Pack) | $146,553 | $120,40419 claims |
| PfizerPanzyga | $9,997 | $73,52112 claims |
| Johnson & JohnsonSimponi | $7,221 | $71,53112 claims |
| Radius Health, Inc.Tymlos | $301 | $37,16412 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $38 | $13,410165 claims |
| AstraZenecaNexium | $671 | $3,24712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 rheumatology providers in Georgia.
Other rheumatology in Tifton
- Gary MyersonAtlanta$1M
- Theresa Lawrence FordLawrenceville$410K
- William WilsonAtlanta$344K
- Jefrey LiebermanDecatur$247K
- Mohammed AbubakerMarietta$218K
- James HuntThomasville$160K
- Omar KhanCumming$145K
- Paul SutejAtlanta$140K
- Sung LimAtlanta$125K
- Cynthia ElliottLawrenceville$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.